Goodbye PCOS, Hello SMOP: Why This Name Change Can Finally Improve Diagnoses

This is a small revolution in the world of women's health that has just been announced at the European Congress of Endocrinology in Prague. The polycystic ovary syndrome is officially changing its name to SMOP, a major evolution for the recognition and management of this condition that affects one in eight women.

The Term Cyst Was a Scientific Error

For decades, the term polycystic ovary syndrome misled patients and caregivers. In reality, this disease has nothing to do with ovarian cysts. Research has proven that what doctors observed on ultrasound was an accumulation of follicles, immature oocytes whose development has been halted. This semantic confusion has long weighed on women, leading to diagnostic wandering and sometimes inadequate care.

Professor Helena Teede, who led this name change process detailed in the journal _The Lancet_00717-8/fulltext) on May 12, 2026, explains that this modification is the result of fourteen years of work. By renaming the disease SMOP, or Metabolic Ovarian Polyendocrine Syndrome, the scientific community is finally correcting the course. This new name allows for setting aside the erroneous image of a purely anatomical pathology to focus on its true nature: a complex hormonal and metabolic imbalance.

SMOP Encompasses Women's Overall Health

The new name accurately reflects the biological reality of the condition. The term polyendocrine reminds us that the problem is primarily hormonal, involving excessive production of androgens such as testosterone. This manifests as symptoms that are often difficult to live with daily, such as acne, hirsutism, or hair loss. But the addition of the word metabolic is undoubtedly the most significant advancement for patient health.

This precision highlights that SMOP does not only impact fertility or physical appearance. It increases the risks of developing type 2 diabetes, hypertension, or cardiovascular diseases. By clearly identifying these risks, medical personnel will now be able to offer much broader monitoring. The goal is to no longer settle for treating visible symptoms but to protect women's overall health in the long term.

Hope for Earlier Screening from Adolescence

The first signs of the syndrome often appear as early as puberty, with very irregular cycles or severe acne. Better naming the disease will allow families and general practitioners to be more vigilant from the first years following menstruation. Appropriate management can greatly improve the quality of life for young girls and prevent future complications.

Regarding fertility, while SMOP is the leading cause of female infertility, the vast majority of affected women manage to carry a pregnancy to term. A transition period of three years is planned for this new name to be firmly established in medical practices. This historic step marks the end of a reductive view of women's health and paves the way for more targeted research to finally treat the cause rather than the consequences.